Growth equity for Indian life-sciences businesses, with distinct domestic and IFSC fund structures.
InvAscent is an India-focused life-sciences private-equity platform providing growth capital to small and mid-sized businesses. For a family investment office, the relevant diligence concerns an allocation to the appropriate fund, its actual manager and the concentration and liquidity of a specialist healthcare portfolio. Portfolio-company corporate-finance support is not evidence of a separate retail brokerage, custody or personal wealth-advice service.
The company focuses on pharmaceuticals, healthcare delivery, medical devices, animal health, specialty ingredients and health technology. It describes working with portfolio management on strategy, business development, corporate finance and governance alongside growth capital. These are descriptions of the investment and portfolio-support approach, not guarantees that a business will grow, raise further capital or exit at a particular value.
The website states that the platform was established in 2005 and reports four funds, more than US$850 million of assets under management, 40 investments and 21 exits. The reviewed homepage gives no measurement date or detailed AUM definition. Treat these as company-reported, undated platform figures rather than a current audited fund balance or a subscription-capacity statement.
Its fund summaries separately list Fund I with eight investments fully realised, Fund II with 12 investments and ten realised, Fund III with 13 investments and three realised, and Fund IV with seven investments. These counts are not return measures, and realised investments do not establish an investor's distributions or IRR. The homepage's 150-plus years of life-sciences experience and team page's 200-plus years of collective cross-sector experience are different experience statements, not employee totals.
The domestic registration page names India Life Sciences Fund IV Domestic, managed by ILSF Lifesciences Manager LLP, with Category II AIF registration IN/AIF2/23-24/1403 and Axis Trustee Services Limited as trustee. It identifies Anil Jagirdar as that fund's compliance officer. The published particulars are not independently verified current registration certificates.
The separately linked IFSC entity-details document names InvAscent ILSF Manager LLP as a registered non-retail Fund Management Entity, with number IFSCA/FME/II/2023-24/066 and a stated registration date of 3 April 2023. It lists India Life Sciences Fund IV as a Category II restricted scheme, IFSC/AIF2/2023-24/0058 dated 2 June 2023, and VistaJect Fund as a Category II restricted scheme, IFSC/AIF2/2024-25/0135 dated 30 May 2024. Both list that IFSC manager.
The domestic fund, IFSC schemes, managers and trustee are distinct published structures. Confirm the actual vehicle, eligibility, jurisdiction, currency, contracting entity and current availability in the placement and subscription documents. No open subscription window, universal family-office eligibility or retail permission is inferred from these particulars.
The company publishes biographies for 17 named team members spanning investment, financial, compliance, environmental and social, human-resources and administrative experience. It lists Hari Buggana and T. P. Devarajan among its experienced professionals. The existing professional profile reports Shweta Agrawal as CFO; the current company team establishes her listed association, while its reference to CFO work at SBICAP Ventures and Paragon describes earlier jobs. That biography is not treated as a new independent current-CFO appointment certificate.
The IFSC details name Hemant Ajmera as Principal Officer and Bhavesh Sonesara as Compliance Officer. The regulatory-disclosures page separately names them as Complaint Redressal Appellate Officer and Complaint Redressal Officer respectively. Those IFSC capacities should not be substituted for Anil Jagirdar's domestic-fund compliance role.
The reviewed public pages and linked grievance documents do not establish an LP minimum commitment, management fee, performance allocation or carry, hurdle, operating-expense cap, fund duration, capital-call schedule, redemption entitlement or transfer fee. Obtain the complete fund-specific fee and expense disclosures, taxes, valuation and reporting policies, conflicts, transfer and exit restrictions, key-person terms and subscription conditions before committing. A standard AIF minimum or fee is not assumed.
A specialist private-equity allocation can involve sector concentration, illiquidity, uncertain valuations and the risk of loss. Realised investment counts, past career experience and regulatory registration are not guarantees of returns, capital protection or a timely exit. Establish how the selected vehicle's mandate and cash-flow profile fit the investor's own portfolio.
The website publishes Plot No. 1174A, Road No. 56, Jubilee Hills, Hyderabad, Telangana, India – 500033; telephone +91 (40) 23541305; and info@invascent.com. The domestic fund's published compliance route is anil.jagirdar@invascent.com at that telephone number. These are company-published contacts, not a universal response guarantee.
For the IFSC fund's investor complaints, the linked policy names Bhavesh.sonesara@invascent.com and a registered office at Unit No. 1505 A Signature, Fifteen Floor, Block 13B Zone-1 GIFT SEZ Gandhinagar, Gujarat, 382355. It states acknowledgement within two business days and that the CRO will strive to provide redressal within ten business days. Its escalation clause separately uses ten days without expressly repeating business days; an unsatisfied investor may escalate to Hemant.ajmera@invascent.com. The document then provides an IFSCA route, preferably within 21 days of the appellate decision, and agreement-based conciliation or arbitration. These are scoped policy conditions, not a universal legal SLA. Fraud, legal-input and third-party cases may receive a communicated turnaround time.
A separate two-page Fund IV stakeholder grievance mechanism addresses adverse impacts of the fund or its portfolio companies and supplies esg@invascent.com. It describes acknowledgement in 24–48 hours, a response formulation period of 24–48 hours up to 25 days depending on complexity, and an additional 15–30 days for appeal. Its anonymous written route separately describes receipt within three working days and a written response within seven business days, using a Hyderabad address printed as Plot 1174. These routes and timings are not harmonised with the IFSC investor-complaint policy or treated as a relocation announcement. Ask which procedure covers the issue.
The investor policy excludes anonymous complaints except whistleblower complaints, incomplete or unsupported allegations, guidance requests and matters outside the regulated entity's financial products or services. The distinct stakeholder mechanism permits an anonymous route. Both linked documents are undated in the reviewed text; upload-folder dates are not assumed to be policy dates.
No. The website reports more than US$850 million at platform level without an established as-of date or full definition in these sources.
No. They have separately named managers, registrations and investor processes. Use the actual selected vehicle's documents and contacts.
No numerical investor tariff, commitment minimum or redemption right was established. Obtain the complete commercial and subscription terms.
Platform figures and fund counts; Strategy and portfolio support; Company team biographies; Domestic fund registration particulars; IFSC disclosures and complaint officers; IFSC manager and scheme particulars; Investor complaint policy; Stakeholder grievance mechanism.
Strengths. Explicit life-sciences growth-equity mandate; Named financial and complaint officers by vehicle; Useful public investor and stakeholder grievance documents.
Watch-outs. No public numerical LP fee/minimum or liquidity terms established; Company scale and investment counts undated, not audited current balances; No current independent appointment certificate for retained professional CFO title; Website modal misheading affects two team biographies; identities kept separate.
Built for Institutional Investors.
Company office: Plot No. 1174A, Road No. 56, Jubilee Hills, Hyderabad, Telangana, India – 500033. Telephone: +91 (40) 23541305. General email: info@invascent.com. Domestic fund compliance: anil.jagirdar@invascent.com. IFSC investor CRO: Bhavesh.sonesara@invascent.com; CRAO: Hemant.ajmera@invascent.com. IFSC policy acknowledgement 2 business days, CRO strives for 10 business days; separate escalation uses 10 days and IFSCA preferably 21 days after CRAO decision. Stakeholder ESG route: esg@invascent.com with distinct published conditions and timings; no universal SLA.
Confirm exact domestic or IFSC fund, manager, jurisdiction, eligibility, currency, availability, placement/subscription documents, capital calls, valuation, reporting, fees/conflicts and transfer/exit restrictions. No universal onboarding timetable or retail entitlement.
Weekly intelligence on tools, providers and strategy — curated for family-office professionals. No noise, no spam.